Arvinas, Inc. Files 8-K Report

TL;DR

ARVN filed an 8-K, mostly standard disclosures. Keep an eye out for details.

AI Summary

On October 5, 2025, Arvinas, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Arvinas, Inc. is providing updated information to the SEC, which could include financial statements or other material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report without immediate indication of significant new risks or material adverse events.

Key Players & Entities

• Arvinas, Inc. (company) — Registrant
• 0001628280-25-044212 (filing_id) — Accession Number
• October 5, 2025 (date) — Date of Report
• New Haven, Connecticut (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market

Filing Documents

• arvn-20251005.htm (8-K) — 38KB
• arvn-mdsx2025.htm (EX-99.1) — 13KB
• arvn-mdsx2025001.jpg (GRAPHIC) — 227KB
• arvn-mdsx2025002.jpg (GRAPHIC) — 223KB
• arvn-mdsx2025003.jpg (GRAPHIC) — 255KB
• arvn-mdsx2025004.jpg (GRAPHIC) — 180KB
• 0001628280-25-044212.txt ( ) — 1395KB
• arvn-20251005.xsd (EX-101.SCH) — 2KB
• arvn-20251005_lab.xml (EX-101.LAB) — 23KB
• arvn-20251005_pre.xml (EX-101.PRE) — 13KB
• arvn-20251005_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On October 5, 2025, Arvinas, Inc. (the "Company") announced the presentation of late breakin g, positive Phase 1 clinical trial data for ARV-102, a PROteolysis TArgeting Chimera ("PROTAC") leucine-rich repeat kinase 2 ("LRRK2") degrader at at the 2025 International Congress of Parkinson's Disease and Movement Disorders. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On October 5, 2025, the Company announced the presentation of late breaking , positive Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader at at the 2025 International Congress of Parkinson's Disease and Movement Disorders. The Company presented data from two clinical trials: ARV-102-101, a first-in-huma n trial of ARV-102 in healthy volunteers, and ARV-102-103, a trial in patients with Parkinson's disease. Key findings from the clinical trials include: Data from a Phase 1 Single Ascending Dose and Multiple Ascending Dose Clinical Trial in Healthy Volunteers Safety: ARV-102 was generally well tolerated at single doses up to 200 mg and multiple daily doses up to 80 mg, with no discontinuations due to adverse events ("AEs") or serious adverse events ("SAEs") observed in the study population. Pharmacokinetics: ARV-102 exposure increased in a dose-dependent manner in plasma and cerebrospinal fluid ("CSF"), the latter indicating brain penetration. Pharmacodynamics: Repeated daily doses 20 mg resulted in >90% reductions of LRRK2 protein in peripheral blood mononuclear cells ("PBMCs") and >50% reductions in CSF. Pathway Biomarkers: Repeated daily doses of ARV-102 resulted in reduced plasma concentrations of phospho-Rab10T73 and urine concentrations of bis(monoacylglycerol)phosphate ("BMP"), a sensitive biomarker for modulation of the lysosomal pathway downstream of LRRK2. Interim Single Ascending Dose Data from a Phase 1 Clinical Trial in Patients with Parkinson's Disease and CSF Proteomic Data from a Phase 1 Trial in Healthy Volunteers Safety: The Phase 1 clinical trial in patients with Parkinson's included 15 patients treated with ARV-102 and 4 patients treated with placebo. In the trial, single doses of ARV-102 (50 mg or 200 mg) were well tolerated with only mild treatment-related AEs including headache, diarrhea, and nausea; no SAEs occurred. Pharmacokinetics: In patients with Parkinson's disease, ARV-102 exposure in

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the Company's belief that these data highlight the potential PROTAC-mediated LRRK2 degradation, which supports the intensified development of ARV-102 in ongoing studies of patients with Parkinson's disease, and future studies of patients with progressive supranuclear palsy; the Company's plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial of trial in patients with Parkinson's disease (ARV-102-103), and the timing thereof; and the Company's intention, pending data from the multiple dose cohort and investigational new drug clearance, to initiate a Phase 1b trial in patients with progressive supranuclear palsy, and the timing thereof. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "believe," "intends," "plans," "potential," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including the important factors discussed the important factors discussed in the "Risk Factors" sections contained in the Company's quarterly and annual reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this Current Report

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release, dated October 5 , 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: October 6, 2025 By: /s/ Andrew Saik Andrew Saik Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR